Lv3
390 积分 2026-10-04 加入
Comparative Effectiveness of Nintedanib and Pirfenidone in Patients Diagnosed With Idiopathic Pulmonary Fibrosis
1天前
已关闭
Will the anti-fibrotic effects of Nerandomi-Last? FIBRONEER-IPF part 2
1天前
已完结
The effect of Pirfenidone on pulmonary function parameters in post recovery COVID-19 patients with pulmonary fibrosis compared to placebo in a Government Medical College, West Bengal
1天前
已完结
Single‐ and Multiple‐Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese Volunteers
1天前
已完结
Safety, Tolerability and Pharmacokinetics of BI 1015550 in Healthy Male Subjects
1天前
已关闭
Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4b, in Patients with Idiopathic Pulmonary Fibrosis: A Phase 2 Trial
1天前
已关闭
Nintedanib with Add‐on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
1天前
已完结
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial
1天前
已完结
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
1天前
已完结
APSR 2025
1天前
已完结
皖公网安备34019202002308
